These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


354 related items for PubMed ID: 16181827

  • 21. Overview of randomized clinical trials in acute heart failure syndromes.
    Teerlink JR.
    Am J Cardiol; 2005 Sep 19; 96(6A):59G-67G. PubMed ID: 16181824
    [Abstract] [Full Text] [Related]

  • 22. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
    Nieminen MS, Sandell EP.
    Ital Heart J; 2003 May 19; 4 Suppl 2():39S-44S. PubMed ID: 14635369
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
    Yontar OC, Yilmaz MB, Yalta K, Tandoğan I.
    Anadolu Kardiyol Derg; 2010 Aug 19; 10(4):310-6. PubMed ID: 20693125
    [Abstract] [Full Text] [Related]

  • 24. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT.
    Expert Opin Investig Drugs; 2008 Aug 19; 17(8):1143-50. PubMed ID: 18616411
    [Abstract] [Full Text] [Related]

  • 25. Levosimendan: a new option in acute cardiac failure.
    Holley AD, Ziegenfuss M.
    Emerg Med Australas; 2006 Aug 19; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract] [Full Text] [Related]

  • 26. Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients.
    Parissis JT, Farmakis D, Bistola V, Adamopoulos S, Kremastinos DT.
    Am J Cardiol; 2007 Jan 01; 99(1):146-7. PubMed ID: 17196480
    [No Abstract] [Full Text] [Related]

  • 27. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
    Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R.
    Int J Cardiol; 2010 Feb 04; 138(3):281-9. PubMed ID: 18817994
    [Abstract] [Full Text] [Related]

  • 28. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR.
    Heart Fail Monit; 2002 Feb 04; 2(4):129-37. PubMed ID: 12634887
    [Abstract] [Full Text] [Related]

  • 29. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT.
    Am J Cardiol; 2006 Dec 15; 98(12):1641-5. PubMed ID: 17145226
    [Abstract] [Full Text] [Related]

  • 30. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.
    Am J Cardiol; 2006 Jul 01; 98(1):102-6. PubMed ID: 16784930
    [Abstract] [Full Text] [Related]

  • 31. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ.
    Anesth Analg; 2007 Apr 01; 104(4):766-73. PubMed ID: 17377079
    [Abstract] [Full Text] [Related]

  • 32. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
    Husebye T, Eritsland J, Müller C, Sandvik L, Arnesen H, Seljeflot I, Mangschau A, Bjørnerheim R, Andersen GØ.
    Eur J Heart Fail; 2013 May 01; 15(5):565-72. PubMed ID: 23288914
    [Abstract] [Full Text] [Related]

  • 33. Role of levosimendan in sepsis and septic shock.
    Pinto BB, Rehberg S, Ertmer C, Westphal M.
    Curr Opin Anaesthesiol; 2008 Apr 01; 21(2):168-77. PubMed ID: 18443483
    [Abstract] [Full Text] [Related]

  • 34. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, Iliodromitis E, Kremastinos D.
    Am J Cardiol; 2004 May 15; 93(10):1309-12. PubMed ID: 15135713
    [Abstract] [Full Text] [Related]

  • 35. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS, Cleland JG, Eha J, Belenkov Y, Kivikko M, Põder P, Sarapohja T.
    Eur J Heart Fail; 2008 Dec 15; 10(12):1246-54. PubMed ID: 18945637
    [Abstract] [Full Text] [Related]

  • 36. Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study).
    Altenberger J, Parissis JT, Ulmer H, Poelzl G, LevoRep Investigators.
    Eur J Heart Fail; 2010 Feb 15; 12(2):186-92. PubMed ID: 20083626
    [Abstract] [Full Text] [Related]

  • 37. Levosimendan: a new approach for the treatment of patients with severe heart failure. A brief summary based on a clinical case.
    Morais J, Dias B, Pontes N.
    Rev Port Cardiol; 2003 Feb 15; 22(7-8):941-8. PubMed ID: 14587161
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of levosimendan in patients with acute heart failure.
    Fedele F, D'Ambrosi A, Bruno N, Caira C, Brasolin B, Mancone M.
    J Cardiovasc Pharmacol; 2011 Oct 15; 58(4):363-6. PubMed ID: 21697728
    [Abstract] [Full Text] [Related]

  • 39. Beneficial effects of levosimendan in infants with sepsis-associated cardiac dysfunction: report of 2 cases.
    Papoff P, Caresta E, Versacci P, Pinto R, Moretti C, Midulla F.
    Pediatr Emerg Care; 2012 Oct 15; 28(10):1062-5. PubMed ID: 23034494
    [Abstract] [Full Text] [Related]

  • 40. [Levosimendan in heart failure].
    Scelsi L, Campana C, Ghio S, Monti L, Opasich C, De Feo S, Cobelli F, Orlandi M, Di Pasquale G, Tavazzi L.
    Recenti Prog Med; 2004 Oct 15; 95(7-8):376-83. PubMed ID: 15303549
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 18.